XML 133 R20.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-Based Compensation
12 Months Ended
May 31, 2022
Share-based Payment Arrangement, Additional Disclosure [Abstract]  
Stock-Based Compensation

NOTE 11: STOCK-BASED COMPENSATION

Our total stock-based compensation expense for the years ended May 31 was as follows (in millions):

 

 

 

2022

 

 

2021

 

 

2020

 

Stock-based compensation expense

 

$

190

 

 

$

200

 

 

$

168

 

We have two types of equity-based compensation: stock options and restricted stock.

STOCK OPTIONS. Under the provisions of our incentive stock plan, key employees and non-employee directors may be granted options to purchase shares of our common stock at a price not less than its fair market value on the date of grant. Vesting requirements are determined at the discretion of the Compensation and Human Resources Committee of our Board of Directors. Option-vesting periods range from one to four years, with the majority of our options vesting ratably over four years. Compensation expense associated with these awards is recognized on a straight-line basis over the requisite service period of the award.

RESTRICTED STOCK. Under the terms of our incentive stock plan, restricted shares of our common stock are awarded to key employees. All restrictions on the shares expire ratably over a four-year period. Shares are valued at the market price on the date of award. The terms of our restricted stock provide for continued vesting subsequent to the employee’s retirement. Compensation expense associated with these awards is recognized on a straight-line basis over the shorter of the requisite service period or the stated vesting period.

ASSUMPTIONS. The key assumptions for the Black-Scholes valuation method include the expected life of the option, stock price volatility, a risk-free interest rate, and dividend yield. The following table includes the weighted-average Black-Scholes value per share of our stock option grants, the intrinsic value of options exercised (in millions), and the key weighted-average assumptions used in the valuation calculations for options granted during the years ended May 31, followed by a discussion of our methodology for developing each of the assumptions used in the valuation model:

 

 

 

2022

 

 

2021

 

 

2020

 

Weighted-average Black-Scholes value per share

 

$

80.21

 

 

$

44.11

 

 

$

33.97

 

Intrinsic value of options exercised

 

$

150

 

 

$

593

 

 

$

44

 

Black-Scholes assumptions:

 

 

 

 

 

 

 

 

 

Expected lives

 

6.4 years

 

 

6.4 years

 

 

6.4 years

 

Expected volatility

 

 

32

%

 

 

30

%

 

 

23

%

Risk-free interest rate

 

 

0.65

%

 

 

1.32

%

 

 

1.91

%

Dividend yield

 

 

0.983

%

 

 

1.710

%

 

 

1.630

%

The expected life represents an estimate of the period of time options are expected to remain outstanding, and we examine actual stock option exercises to determine the expected life of the options. Options granted have a maximum term of 10 years. Expected volatilities are based on the actual changes in the market value of our stock and are calculated using daily market value changes from the date of grant over a past period equal to the expected life of the options. The risk-free interest rate is the U.S. Treasury Strip rate posted at the date of grant having a term equal to the expected life of the option. The expected dividend yield is the annual rate of dividends per share over the exercise price of the option.

The following table summarizes information regarding stock option activity for the year ended May 31, 2022:

 

 

 

Stock Options

 

 

 

Shares

 

 

Weighted-
Average
Exercise
Price

 

 

Weighted-
Average
Remaining
Contractual
Term

 

 

Aggregate
Intrinsic Value
(in millions)
(1)

 

Outstanding at June 1, 2021

 

 

15,325,497

 

 

$

175.19

 

 

 

 

 

 

 

Granted

 

 

1,812,623

 

 

$

282.12

 

 

 

 

 

 

 

Exercised

 

 

(1,299,961

)

 

 

140.97

 

 

 

 

 

 

 

Forfeited

 

 

(509,734

)

 

 

197.05

 

 

 

 

 

 

 

Outstanding at May 31, 2022

 

 

15,328,425

 

 

$

190.01

 

 

 

6.3

 

 

$

748

 

Exercisable

 

 

8,725,648

 

 

$

182.46

 

 

 

5.0

 

 

$

438

 

Expected to vest

 

 

6,084,501

 

 

$

199.98

 

 

 

8.1

 

 

$

286

 

Available for future grants

 

 

10,824,217

 

 

 

 

 

 

 

 

 

 

(1)
Only presented for options with market value at May 31, 2022 in excess of the exercise price of the option.

The options granted during 2022 are primarily related to our principal annual stock option grant in June 2021.

The following table summarizes information regarding vested and unvested restricted stock for the year ended May 31, 2022:

 

 

 

Restricted Stock

 

 

 

Shares

 

 

Weighted-
Average
Grant Date
Fair Value

 

Unvested at June 1, 2021

 

 

537,281

 

 

$

170.16

 

Granted

 

 

115,172

 

 

$

276.26

 

Vested

 

 

(209,402

)

 

 

181.62

 

Forfeited

 

 

(10,570

)

 

 

191.41

 

Unvested at May 31, 2022

 

 

432,481

 

 

$

192.30

 

During the year ended May 31, 2021, there were 335,004 shares of restricted stock granted with a weighted-average fair value of $155.19 per share. During the year ended May 31, 2020, there were 207,012 shares of restricted stock granted with a weighted-average fair value of $158.58 per share.

Stock option vesting during the years ended May 31 was as follows:

 

 

 

Stock Options

 

 

 

Vested during
the year

 

 

Fair value
(in millions)

 

2022

 

 

3,005,727

 

 

$

138

 

2021

 

 

2,492,039

 

 

$

115

 

2020

 

 

2,073,310

 

 

$

99

 

As of May 31, 2022, there was $253 million of total unrecognized compensation cost, net of estimated forfeitures, related to unvested share-based compensation arrangements. This compensation expense is expected to be recognized on a straight-line basis over the remaining weighted-average vesting period of approximately two years.

Total shares outstanding or available for grant related to equity compensation at May 31, 2022 represented 9% of the total outstanding common and equity compensation shares and equity compensation shares available for grant.